Evidence map›Paper›PMID 27402093›Full record

Trial reportMolecular imaging and biology2017

Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A

Mickael Huiban, Christopher Coello, Kai Wu, Yanmei Xu, Yvonne Lewis, Andrew P Brown, Mauro Buraglio, Chenbing Guan, Shaila Shabbir, Regan Fong and 3 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular imaging and biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01924858 (An Open Label Positron Emission Tomography), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01924858 phase1terminatednot on this map

An Open Label Positron Emission Tomography (PET) Study to Investigate the Brain Biodistribution of 18F-GSK2647544 in Healthy Subjects

TypeinterventionalSponsorGlaxoSmithKlineRan2013 to 2014Enrolled4ConditionsAlzheimer's DiseaseArmsGSK2647544 oral, [18F]GSK2647544 IV bolus
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. New Long-Acting [Journal of medicinal chemistry · 2023
    Article
  2. Review
  3. Small-molecule inhibitors as potential therapeutics and as tools to understand the role of phospholipases ABiochimica et biophysica acta. Molecular and cell biology of lipids · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Mickael HuibanImanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Christopher CoelloImanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Kai WuWuXi Clinical Development Service, 19th Floor, Building A, FuXing Plaza, 388 Ma Dang Road, Shanghai, 200025, China.
Yanmei XuGlaxoSmithKline, Neurosciences, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201203, China.
Yvonne LewisImanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Andrew P BrownAstraZeneca UK Limited, Melbourn Science Park, Royston, Herts, SG8 6HB, UK.
Mauro BuraglioGlaxoSmithKline, Neurosciences, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
Chenbing GuanGlaxoSmithKline, Neurosciences, 917 Halei Road, Zhangjiang Hi-tech Park, Pudong, Shanghai, 201203, China.
Shaila ShabbirGlaxoSmithKline, Neurosciences, Gunnels Wood Road, Stevenage, SG1 2NY, UK.
Regan FongUCB Biosciences Inc, PO Box 110167, Research Triangle Park, NC, 27709, USA.
Jan PasschierImanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Eugenii A RabinerImanova Limited, Burlington Danes Building, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.
Andrew LockhartGlaxoSmithKline, Neurosciences, Clinical Unit Cambridge, Addenbrooke's Hospital, Cambridge, CB2 0GG, UK. andrew.2.lockhart@gsk.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGSK2647544 is a potent and specific inhibitor of lipoprotein-associated phospholipase A PROCEDURES: [

resultsPET dynamic data were successfully obtained from all four subjects and there were no clinically significant variations of the safety endpoints. Inspection of the TACs indicated a relatively homogenous uptake of [

conclusionsThe study provides evidence that GSK2647544 is able to cross the blood brain barrier in healthy male subjects leading to a measurable brain exposure. The administered doses of GSK2647544 were well tolerated. Exploratory modelling suggested that a twice-daily dose of 102 mg, at steady state, would provide ~80 % trough inhibition of brain Lp-PLA

trial registrationClintrials.gov: NCT01924858.

Indexed as

1-Alkyl-2-acetylglycerophosphocholine EsteraseAdultAnimalsBrainFluorine RadioisotopesHumansImage Processing, Computer-AssistedMaleMiceMiddle AgedPhenyl EthersPyrimidinonesRatsTime FactorsTissue Distribution1-Alkyl-2-acetylglycerophosphocholine EsteraseFluorine RadioisotopesGSK2647544Phenyl EthersPyrimidinonesAlzheimer’s diseaseBiodistributionGSK2647544Lp-PLA2PETPositron emission tomography

Identifiers

PMID27402093
PMCPMC5209404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.